Biogen Inc. $BIIB Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Biogen Inc. (NASDAQ:BIIB) by 20.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 196,903 shares of the biotechnology company’s stock after purchasing an additional 33,273 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Biogen were worth $27,582,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BIIB. Syon Capital LLC raised its position in shares of Biogen by 23.0% in the third quarter. Syon Capital LLC now owns 2,770 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 518 shares during the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Biogen in the third quarter worth about $255,000. NEOS Investment Management LLC boosted its position in Biogen by 55.7% during the third quarter. NEOS Investment Management LLC now owns 57,301 shares of the biotechnology company’s stock worth $8,027,000 after acquiring an additional 20,490 shares during the last quarter. Supplemental Annuity Collective Trust of NJ purchased a new stake in Biogen during the 3rd quarter valued at about $322,000. Finally, NJ State Employees Deferred Compensation Plan raised its holdings in Biogen by 107.2% in the 3rd quarter. NJ State Employees Deferred Compensation Plan now owns 5,180 shares of the biotechnology company’s stock valued at $726,000 after acquiring an additional 2,680 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BIIB shares. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Guggenheim boosted their price objective on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Oppenheimer upped their target price on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, January 30th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a report on Monday, February 9th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat, Biogen has an average rating of “Hold” and an average price target of $205.04.

Biogen Stock Performance

NASDAQ BIIB opened at $192.08 on Friday. The stock has a fifty day simple moving average of $179.66 and a 200-day simple moving average of $160.68. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock has a market cap of $28.19 billion, a PE ratio of 21.80, a P/E/G ratio of 1.54 and a beta of 0.16. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.